BioSpace News Archive

Researchers at Vanderbilt University Medical Center are leading a study designed to identify early drivers of pulmonary fibrosis in an at-risk patient population.

Advarra, the market leader in practice management technology for clinical research and regulatory review solutions, today kicked off Onsemble, the premier conference for the research community, which is held over four days.

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the European Medicines Agency (EMA) has authorized a third dose of the Moderna COVID-19 vaccine (Spikevax) given at least 28 days after the second dose to severely immunocompromised individuals 12 years of age or older.

Adial Pharmaceuticals, Inc. today announced that the Company has been invited to present at the Fall Harvest - Best Ideas from the Buy-Side conference, which is being held virtually this week, October 5 - 8, 2021.

The Advance Notice Provisions provide the required form and contents for a Shareholder to give notice and fixes the deadline by which Shareholders must submit director nominations to the Company prior to any annual or special meeting of Shareholders.

BioCina, a leading contract development and manufacturing organization specializing in process development and cGMP manufacturing of microbial-based therapeutics and mRNA vaccines announces the full and final transition from Hospira Adelaide Pty Ltd., an affiliate of Pfizer Inc., of its biologics manufacturing facility, colleagues and operations in Adelaide, Australia.

Carbon Health, a leading national healthcare provider, today announced the acquisition of Alertive Healthcare, an industry-leading remote patient monitoring (RPM) company.

Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the Company’s management will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, announced the Company will be participating in the H.C. Wainwright 5th Annual NASH Investor Conference being held virtually on October 12, 2021.

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), today announced that management will be presenting at the H.C. Wainwright 5th Annual NASH Investor Conference.